Skip to main content

Ascendis Pharma ADR(ASND-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low222.95
Day High233.05
Open:230.76
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Ascendis Pharma ADR

Select a category then submit the form to load news
Tipranks
Ascendis Pharma (ASND) Gets a Buy from Morgan Stanley
Tipranks
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Ascendis Pharma (ASND) and Avalo Therapeutics (AVTX)
Tipranks
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Incyte (INCY) and Radnet (RDNT)
Tipranks
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Sionna Therapeutics, Inc. (SION)
Tipranks
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Intellia Therapeutics (NTLA) and Immunic (IMUX)
Tipranks
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Ascendis Pharma (ASND) and Roche Holding AG (OtherRHHVF)
Tipranks
Ascendis Pharma Wins FDA Accelerated Approval for YUVIWEL in Pediatric Achondroplasia
GlobeNewswire
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
Tipranks
Ascendis Pharma Sets March 23 AGM to Approve 2025 Results, Board Changes and Buyback Mandate
Tipranks
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX)
Motley Fool
Ascendis (ASND) Q4 2025 Earnings Call Transcript
Motley Fool
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
Motley Fool
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
Motley Fool
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
Motley Fool
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
Tipranks
Morgan Stanley Remains a Buy on Ascendis Pharma (ASND)
Tipranks
Ascendis Pharma Earnings Call Highlights Growth Momentum
Tipranks
Oppenheimer Keeps Their Buy Rating on Ascendis Pharma (ASND)
Tipranks
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Humana (HUM)
Tipranks
RBC Capital Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
Tipranks
Ascendis Pharma Posts Strong 2025 Results as YORVIPATH Drives Growth and TransCon Pipeline Advances
Tipranks
Ascendis Pharma Grants New Employee Warrants, Updates Articles to Support Future Equity Issuances
Motley Fool
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript
GlobeNewswire
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
Tipranks
Morgan Stanley Sticks to Its Buy Rating for Ascendis Pharma (ASND)
Newswire.ca
Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults
GlobeNewswire
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
Tipranks
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND) and Abivax SA Sponsored ADR (ABVX)
Tipranks
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC) and Ascendis Pharma (ASND)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Ascendis Pharma (ASND)

Profile

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.